Afamelanotide (Scenesse) for Vitiligo: Trial Data and Availability
Afamelanotide (brand name Scenesse) is a synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH) — a naturally occurring melanocortin peptide that stimulates melanocyte proliferation and melanin production. It was approved by the European Medicines Agency for erythropoietic protoporphyria (a rare light-sensitivity disorder) in 2014, and it has been studied as a vitiligo treatment — specifically as a phototherapy enhancer — in combination with narrowband UVB.
What afamelanotide does
α-MSH (melanocyte-stimulating hormone) is the body’s natural signal for melanocytes to activate and produce melanin. In normal skin, UV exposure triggers α-MSH release, which instructs melanocytes to proliferate and ramp up melanin synthesis — producing a tan.
Afamelanotide is a more potent, longer-acting synthetic version of this signal. Administered as a subcutaneous implant (placed under the skin), it releases slowly over four to six weeks, providing sustained melanocyte stimulation above what the body would normally produce.
The concept for vitiligo: by providing powerful, sustained melanocyte stimulation, afamelanotide could amplify the repigmentation response to phototherapy — maximising the activation of whatever surviving melanocyte reservoir remains in vitiligo patches.
The trial data
The most significant vitiligo trial of afamelanotide was published in JAMA Dermatology in 2015 (Grimes et al.). This randomised controlled trial enrolled 55 patients with non-segmental vitiligo and compared:
- Afamelanotide implant (16mg subcutaneous every four weeks) + narrowband UVB
- Placebo implant + narrowband UVB
Results at 26 weeks:
- The combination group showed significantly more rapid repigmentation onset — colour returned faster in the afamelanotide group
- Darker skin types (Fitzpatrick III–VI) showed particularly pronounced benefit from afamelanotide
- The extent of total repigmentation at 26 weeks was greater in the combination group compared to NbUVB alone
- The benefit was most pronounced on sun-exposed areas (face, arms) — consistent with the drug’s mechanism requiring UV activation of the stimulated melanocytes
Adverse effects were generally mild: nausea, fatigue, flushing, and skin darkening of normal skin (an expected pharmacological effect given melanocyte stimulation).
Why darker skin types respond better
This is mechanistically interesting. Afamelanotide stimulates all melanocytes — including those in normal skin — to produce more melanin. In patients with darker baseline skin tone, the melanocytes are already more active, and the additional stimulation produces more dramatic repigmentation in vitiligo patches. In lighter-skinned patients, the baseline melanocyte activity is lower, limiting the amplification effect.
This suggests afamelanotide combined with phototherapy may have its greatest utility in patients with skin types III–VI — precisely the population where vitiligo visibility and impact is often highest.
Availability and cost
Afamelanotide is not approved for vitiligo in any jurisdiction. It is approved in Europe and the US for erythropoietic protoporphyria only — its use for vitiligo is off-label.
This creates significant access challenges:
In the US: Scenesse is approved for erythropoietic protoporphyria but not for vitiligo. Off-label prescribing is legal but requires a willing prescriber, and insurance will not cover off-label vitiligo use. The cost is extremely high — tens of thousands of dollars per year for on-label use.
In Europe: Available on-label for protoporphyria in many countries; off-label vitiligo use faces the same insurance coverage issues. Not accessible through standard dermatology pathways.
Via clinical trials: The most practical route for most patients who are interested in afamelanotide for vitiligo is participation in an ongoing clinical trial. Trial participants receive the drug at no cost under controlled conditions. See the vitiligo clinical trials guide for how to find active trials.
Combining with home phototherapy
The trial data uses clinic-based NbUVB as the phototherapy component. Whether home narrowband UVB combined with afamelanotide would produce the same results has not been specifically studied, but the mechanism supports the concept — the phototherapy activates the stimulated melanocytes regardless of whether it is administered in a clinic or at home.
Current status
Afamelanotide for vitiligo remains a research-stage treatment rather than a clinically available option for most patients. The trial data is promising — particularly the signal in darker skin types — but it needs replication in larger trials before it would be considered for regulatory submission for a vitiligo indication.
For patients with moderate to severe vitiligo of Fitzpatrick type III–VI who are seeking phototherapy enhancement, afamelanotide represents an interesting future option. The vitiligo clinical trials guide covers how to access it through trial participation. The vitiligo treatment options comparison covers the currently available options.
